FDA Grants Approval for Irbesartan ANDA077205 by Chartwell Molecular
The FDA has granted approval for ANDA077205, a supplemental application for Irbesartan submitted by Chartwell Molecular.
Asset / Drug
Drug and asset intelligence for Irbesartan with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Sandoz's ANDA077446 for Irbesartan and Hydrochlorothiazide has received an Abbreviated Approval (AP) status.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.